NCT03420768View on ClinicalTrials.gov

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

December 10, 2018

Study Completion Date

May 28, 2019

Conditions
Hepatic CirrhosisLiver Fibrosis
Interventions
DRUG

BMS-986263

Administered by intravenous (IV) infusion

OTHER

Placebo

Administered by intravenous (IV) infusion

Trial Locations (1)

78215

The Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03420768 - A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C | Biotech Hunter | Biotech Hunter